Cytogam Related Published Studies
Well-designed clinical trials related to Cytogam (Cytomegalovirus Immune Globulin)
A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic
stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase
2 trial. [2012]
Cytomegalovirus infection and responsiveness to influenza vaccination in elderly residents of long-term care facilities. [2011.06.24]
Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. [2011.04.09]
Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. [2010.12.27]
Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. [2009.12.11]
Vaccine prevention of maternal cytomegalovirus infection. [2009.03.19]
Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. [2008.02.15]
Role of cytomegalovirus in sensorineural hearing loss of children: a case-control study Tehran, Iran. [2008.02]
Effects of Jinye Baidu Granule on fetal growth and development with maternal active human cytomegalovirus infection. [2006.12]
Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12. [2006.06.19]
A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. [2006.05.15]
Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients. [2006.04]
Detection of cytomegalovirus infection during a vaccine clinical trial in healthy young women: seroconversion and viral shedding. [2006.03]
A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients. [2005.09]
[Observation on clinical efficacy of combined therapy of zinc supplement and jinye baidu granule in treating human cytomegalovirus infection] [2005.05]
Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. [2005.05]
Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation. [2005.05]
Lack of induction of autoantibody responses following immunization with cytomegalovirus (CMV) glycoprotein B (gB) in healthy CMV-seronegative subjects. [2004.12.16]
A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis. [2004.11]
Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients. [2004.04]
Urine polymerase chain reaction as a screening tool for the detection of congenital cytomegalovirus infection. [2003.09]
Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients. [2003.07]
Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients. [2003.01.27]
Visual loss in patients with cytomegalovirus retinitis and acquired immunodeficiency syndrome before widespread availability of highly active antiretroviral therapy. [2003.01]
HIV and cytomegalovirus viral load and clinical outcomes in AIDS and cytomegalovirus retinitis patients: Monoclonal Antibody Cytomegalovirus Retinitis Trial. [2002.04.12]
Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults. [2002.03.01]
Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. [2002.02]
A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. [2001.04.15]
Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. [2001]
Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir. [2000.03]
Cytomegalovirus immune globulin after liver transplantation: a cost-effectiveness analysis. [2000.02]
Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine. [1999.11]
A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. [1999.10]
Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche Study Group. [1999.07.27]
[The experimental and clinical study of inhibitory effects of Re-Du-Qing on human cytomegalovirus (HCMV)] [1999.06.30]
Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease: a prospective study in middle-aged to elderly men with treated hypertension. [1999.02]
A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients. [1998.12.27]
Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection. [1998.12]
A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT). [1998.02]
Clinical course of cytomegalovirus (CMV) viremia with and without ganciclovir treatment in CMV-seropositive kidney transplant recipients. Longitudinal follow-up of CMV pp65 antigenemia assay. [1998]
Randomized comparison of ganciclovir plus intravenous immune globulin (IVIG) with IVIG alone for prevention of primary cytomegalovirus disease in children receiving liver transplants. [1997.11]
Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. [1997.10]
No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group. [1997.02]
Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy. [1997.01]
Incidence and predictors of cytomegalovirus pneumonia in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group. [1996.06.27]
Long-term ganciclovir prophylaxis eliminates serious cytomegalovirus disease in liver transplant recipients receiving OKT3 therapy for rejection. [1995.12.15]
A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. [1995.11.01]
Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients. [1995.11]
Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. [1995.10.01]
Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. [1995.07.08]
Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. [1995.07.01]
Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3. [1995.07]
Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. [1995.01]
Use of cytomegalovirus immunoglobulin in multiply transfused premature neonates. [1995.01]
Prophylaxis of primary cytomegalovirus disease in renal transplant recipients. A trial of ganciclovir vs immunoglobulin. [1994.04]
A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation. [1994.03.27]
Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients--a meta-analysis. [1994.02]
Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. [1993.11.15]
Failure of high-dose oral acyclovir with or without immune globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplants. [1993.09]
Early detection of primary cytomegalovirus infection after heart and kidney transplantation and the influence of hyperimmune globulin prophylaxis. [1993.01]
Circulating cytomegalovirus (CMV) neutralizing activity in bone marrow transplant recipients: comparison of passive immunity in a randomized study of four intravenous IgG products administered to CMV-seronegative patients. [1992.11.15]
A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. [1992.04.30]
The effect of polyimmune gammaglobulin for prophylaxis against reactivation cytomegalovirus infection in kidney and kidney/pancreas transplant recipients. [1992.04]
Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant. [1991.09]
Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. [1991.04.01]
Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening. [1991.03]
Intravenous immunoglobulin infusions for the prophylaxis of secondary cytomegalovirus infection. [1990.01]
Polyvalent immune globulin and cytomegalovirus infection after renal transplantation. [1989.12]
Cytomegalovirus infections in seropositive patients after transfusion. The effect of red cell storage and volume. [1989.10]
[Prevention of cytomegalic inclusion disease in leukemia patients with a cytomegalovirus hyperimmune globulin preparation] [1989.07]
Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Neonatal Cytomegalovirus Infection Study Group. [1989.06.03]
Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. [1987.10.22]
Failure to prevent cytomegalovirus infection by cytomegalovirus hyperimmune plasma: a randomized trial by the Nordic Bone Marrow Transplantation Group. [1987.10]
[Clinical and biological evaluation of the preventive role of anti-cytomegalovirus specific immunoglobulins in bone marrow grafts. Randomized study of 60 patients] [1987]
Well-designed clinical trials possibly related to Cytogam (Cytomegalovirus Immune Globulin)
Serological evidence of exposure to Herpes Simplex Virus type 1 is associated with cognitive deficits in the CATIE schizophrenia sample. [2011.05]
Construction and analysis of the immune effect of an Edwardsiella tarda DNA vaccine encoding a D15-like surface antigen. [2011.01]
Serological evidence of exposure to Herpes Simplex Virus type 1 is associated
with cognitive deficits in the CATIE schizophrenia sample. [2011]
IL-2 immunotherapy to recently HIV-1 infected adults maintains the numbers of IL-17 expressing CD4+ T (T(H)17) cells in the periphery. [2010.09]
Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. [2010.09]
Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial. [2010.07.27]
Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. [2010.06.27]
Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. [2010.06]
Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. [2010.04]
Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy
after lung transplantation. [2010]
A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. [2009.09.27]
[Two-dose steroid combined with two-dose daclizumab and tacrolimus regimen in liver transplant recipients] [2009.07.15]
A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. [2009.05.15]
Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. [2009.05]
A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain). [2009.03.04]
Results of a phase I/II British Society of Bone Marrow Transplantation study on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic stem cell transplantation. [2009.02]
20-year follow-up results of a randomized controlled trial comparing antilymphocyte globulin induction to no induction in renal transplant patients. [2008.12.27]
A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. [2008.10.15]
Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation. [2008.10.08]
CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A. [2008.06]
A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation. [2008.01]
Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. [2007.12.10]
Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. [2007.11]
A randomized, controlled trial of daclizumab vs anti-thymocyte globulin induction for lung transplantation. [2007.05]
Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. [2007.04.15]
Very early steroid withdrawal in simultaneous pancreas-kidney transplants. [2007.03]
Rabbit antithymocyte globulin versus basiliximab in renal transplantation. [2006.11.09]
|
